These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 16619536)
1. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Cory AH; Chen J; Cory JG Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536 [TBL] [Abstract][Full Text] [Related]
2. Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01. Cory AH; Somerville L; Cory JG Anticancer Res; 2005; 25(1A):101-6. PubMed ID: 15816525 [TBL] [Abstract][Full Text] [Related]
3. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells. Cory AH; Cory JG Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998 [TBL] [Abstract][Full Text] [Related]
4. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Somerville L; Cory JG Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634 [TBL] [Abstract][Full Text] [Related]
5. Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells. He AW; Cory JG Oncol Res; 1998; 10(9):455-64. PubMed ID: 10223621 [TBL] [Abstract][Full Text] [Related]
6. Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation. Cory AH; Cory JG Anticancer Res; 2001; 21(6A):3807-11. PubMed ID: 11911251 [TBL] [Abstract][Full Text] [Related]
7. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488 [TBL] [Abstract][Full Text] [Related]
8. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053 [TBL] [Abstract][Full Text] [Related]
9. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. Orue A; Chavez V; Strasberg-Rieber M; Rieber M BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474 [TBL] [Abstract][Full Text] [Related]
10. Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells. He AW; Cory JG Int J Oncol; 1999 May; 14(5):891-5. PubMed ID: 10200338 [TBL] [Abstract][Full Text] [Related]
11. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247 [TBL] [Abstract][Full Text] [Related]
12. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells. Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545 [TBL] [Abstract][Full Text] [Related]
13. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036 [TBL] [Abstract][Full Text] [Related]
14. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Liang Y; Besch-Williford C; Hyder SM Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255 [TBL] [Abstract][Full Text] [Related]
15. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Wang T; Lee K; Rehman A; Daoud SS Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036 [TBL] [Abstract][Full Text] [Related]
16. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627 [TBL] [Abstract][Full Text] [Related]
17. Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors. Somerville L; Cory JG Anticancer Res; 1999; 19(2A):1021-6. PubMed ID: 10368649 [TBL] [Abstract][Full Text] [Related]
18. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc. Farhadi E; Safa M; Sharifi AM; Bashash D Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348 [TBL] [Abstract][Full Text] [Related]